Drug intelligence / Profile preview

DONU

Development stage: Preclinical
Modality: Small Molecules

Overview

DONU is a derivative of water-soluble nitrosourea, a class of cytotoxic chemotherapeutic agents. Nitrosoureas exert their anticancer activity primarily by alkylating and carbamoylating DNA, which interferes with DNA replication and repair, ultimately leading to cell death. This class of drugs is known for its lipophilicity, enabling it to cross the blood-brain barrier, making them useful in treating brain tumors. DONU has shown effects on human tumors serially transplanted into nude mice.

Targets

DNA

Beyond the preview

Go deeper on DONU.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DONU.